Prior view was $10.75-$10.95, consensus $10.50. Maintains FY25 adjusted operational sales growth 2%-3%, consensus $90.29B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Notable companies reporting before tomorrow’s open
- Johnson & Johnson (JNJ) Stands Firm as Recession-Resistant Tariff-Proof Anchor
- Johnson & Johnson price target lowered to $162 from $165 at Raymond James
- Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke
- Options Volatility and Implied Earnings Moves This Week, April 14 – April 17, 2025